Crossmark

Antimicrobial Treatment Options for Difficult-to-Treat Resistant Gram-Negative Bacteria Causing Cystitis, Pyelonephritis, and Prostatitis: A Narrative Review

Crossref DOI link: https://doi.org/10.1007/s40265-022-01676-5

Published Online: 2022-03-14

Published Print: 2022-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Chou, Andrew

Welch, Elwyn

Hunter, Andrew

Trautner, Barbara W. https://orcid.org/0000-0001-7986-9099
Funding

Funding for this research was provided by:

Health Services Research and Development (IIR 16-025)

Rehabilitation Research and Development Service (I01 RX002595)

Clinical Science Research and Development (IK2 CX001981)
License Information

Text and Data Mining valid from 2022-03-01

Version of Record valid from 2022-03-01
More Information

Article History

Accepted: 11 January 2022

First Online: 14 March 2022

Declarations

:

: This work is supported by VA HSR&D IIR 16-025 (to BWT), I01 RX002595 from VA RR&D (to BWT), IK2 CX001981 from VA CSR&D (to AC), and by the Center for Innovations in Quality, Effectiveness and Safety (CIN 13-413) at the Michael E. DeBakey VA Medical Center, Houston, TX, USA. Some of the authors are employees of the US Government, and the contents of this article do not necessarily represent the views of the US Department of Veterans Affairs or the US Government.

: BWT received research support from Genentech, Zambon Pharmaceuticals, AHRQ, VA RR&D, and VA HSR&D. BTW is also a faculty member for the George Washington University Infectious Diseases Board Review course. AC, EW, and AH report no conflicts of interest.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: AC: conceptualization. AC, EW, AH: literature review, writing, reviewing, editing. BWT: conceptualization, reviewing, editing, supervision, project leadership.

Document is current

Any future updates will be listed below